Difference between revisions of "PATO Meeting"

From NCBO Wiki
Jump to navigation Jump to search
m (Reverted edit of Googlefans, changed back to last version by Sjcarbon)
Line 2: Line 2:
 
The [http://ncbo.us National Center for Biomedical Ontology] will host a two-day meeting focused on the [http://obo.sourceforge.net/cgi-bin/detail.cgi?attribute_and_value Phenotype and Trait Ontology (PATO)] December 1-2, 2006 at Stanford University in Palo Alto, CA.
 
The [http://ncbo.us National Center for Biomedical Ontology] will host a two-day meeting focused on the [http://obo.sourceforge.net/cgi-bin/detail.cgi?attribute_and_value Phenotype and Trait Ontology (PATO)] December 1-2, 2006 at Stanford University in Palo Alto, CA.
  
[http://www.fruitfly.org/pato/pato-form.html Register here.][http://www.wow-gold-sell.com/ wow gold]
+
[http://www.fruitfly.org/pato/pato-form.html Register here.]
  
 
==Draft agenda==
 
==Draft agenda==

Revision as of 17:20, 11 August 2006

General Information

The National Center for Biomedical Ontology will host a two-day meeting focused on the Phenotype and Trait Ontology (PATO) December 1-2, 2006 at Stanford University in Palo Alto, CA.

Register here.

Draft agenda

  • Thursday, November 30, 2006
    • 7pm: Informal gathering for dinner (Gordon Biersch?)
  • Friday, December 1, 2006
    • 8:30 - 5:30pm Meeting
      • Introduction to PaTO
      • Phenote
  • Saturday, December 2, 2006
    • 8:30 - 5:30pm Meeting

Venue

Stanford University Clark Center, room S360

Directions to Stanford Medical Center

Map of Stanford Medical Center--see "C", Clark Center

Directions on taking Free Marguerite Shuttle Bus--take Line A to Medical Center

Accommodations

We aren't reserving a block of rooms anywhere, but these local hotels are close by and have Stanford shuttle service.

Talk List

Russ Altman: Challenges for Representing Phenotype in Pharmacogenomics

  • Abstract: The PharmGKB (http://www.pharmgkb.org/) is an online resource devoted to comprehensive cataloguing of genetic variations relevant to variation in drug response. We curate primary data (genotype, phenotype at molecular, cellular, clinical level) as well as knowledge (literature curation, pathways, human annotations of key genes). We provide search and visualization tools for this information, in order to catalyze research in pharmacogenomics. For both activities, we need to index the relevant phenotypes for the purposes of indexing, aggregation, search, and automatic summarization and data mining. We need a flexible method for annotating phenotypes that are described in the literature (by curators). We would prefer to adopt community-based standards that would allow PharmGKB to interoperate with other databases, both human and model organism.